A Phase I, Two Parts Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of BAR502 in Healthy Subjects
Latest Information Update: 29 Nov 2024
Price :
$35 *
At a glance
- Drugs BAR 502 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; First in man
- Sponsors Bar Pharmaceuticals
- 29 Nov 2024 New trial record